NFIB is a potential target for estrogen receptor-negative breast cancers

Molecular Oncology

Volumn 5, Issue 6, 2011, Pages 538-544

  Moon, Hyeong Gon ^a   Hwang, Ki Tae ^b   Kim, Jeong Ah ^a   Kim, Hee Sung ^c   Lee, Min Joo ^a   Jung, Eun Mi ^a   Ko, Eunyoung ^a   Han, Wonshik ^a   Noh, Dong Young ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Korea Electric Power Research Institute (KEPRI)   (South Korea)

Author keywords

Breast Cancer; ER; NFIB; Target; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; NUCLEAR FACTOR; NUCLEAR FACTOR I B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

EID: 81855166112     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.08.002     Document Type: Article

References (25)

1. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., Mandelblatt J.S., Yakovlev A.Y., Habbema J.D., Feuer E.J. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 2005, 353:1784-1792.
2. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
3. EBCTBG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
4. Fujita S., Ito T., Mizutani T., Minoguchi S., Yamamichi N., Sakurai K., Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol. 2008, 378:492-504.
5. Geurts J.M., Schoenmakers E.F., Roijer E., Astrom A.K., Stenman G., van de Ven W.J. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 1998, 16:865-872.
6. Gronostajski R.M. Roles of the NFI/CTF gene family in transcription and development. Gene 2000, 249:31-45.
7. Grunder A., Ebel T.T., Mallo M., Schwarzkopf G., Shimizu T., Sippel A.E., Schrewe H. Nuclear factor I-B (Nfib) deficient mice have severe lung hypoplasia. Mech. Dev. 2002, 112:69-77.
8. Han W., Jung E.M., Cho J., Lee J.W., Hwang K.T., Yang S.J., Kang J.J., Bae J.Y., Jeon Y.K., Park I.A., Nicolau M., Jeffrey S.S., Noh D.Y. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer 2008, 47:490-499.
9. Hannafon B.N., Sebastiani P., de Las Morenas A., Lu J., Rosenberg C.L. Expression of microRNAs and their gene targets are dysregulated in pre-invasive breast cancer. Breast Cancer Res. 2011, 13:R24.
10. Italiano A., Ebran N., Attias R., Chevallier A., Monticelli I., Mainguene C., Benchimol D., Pedeutour F. NFIB rearrangement in superficial, retroperitoneal, and colonic lipomas with aberrations involving chromosome band 9p22. Genes Chromosomes Cancer 2008, 47:971-977.
11. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2):69-90.
12. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., Coebergh J.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur. J. Cancer 2008, 44:1345-1389.
13. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., van de Vijver M.J. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007, 9:R65.
14. Mitani Y., Li J., Rao P.H., Zhao Y.J., Bell D., Lippman S.M., Weber R.S., Caulin C., El-Naggar A.K. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin. Cancer Res. 2010, 16:4722-4731.
15. Moon H.G., Jeong S.H., Ju Y.T., Jeong C.Y., Lee J.S., Lee Y.J., Hong S.C., Choi S.K., Ha W.S., Park S.T., Jung E.J. Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res. Treat. 2010, 42:151-156.
16. Nagata K., Guggenheimer R.A., Enomoto T., Lichy J.H., Hurwitz J. Adenovirus DNA replication in vitro: identification of a host factor that stimulates synthesis of the preterminal protein-dCMP complex. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:6438-6442.
17. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 2006, 3:269-280.
18. Nilsson M., Panagopoulos I., Mertens F., Mandahl N. Fusion of the HMGA2 and NFIB genes in lipoma. Virchows Arch. 2005, 447:855-858.
19. Persson M., Andren Y., Mark J., Horlings H.M., Persson F., Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18740-18744.
20. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
21. Pierron A., Fernandez C., Saada E., Keslair F., Hery G., Zattara H., Pedeutour F. HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. Cancer Genet. Cytogenet. 2009, 195:66-70.
22. Qian F., Kruse U., Lichter P., Sippel A.E. Chromosomal localization of the four genes (NFIA, B, C, and X) for the human transcription factor nuclear factor I by FISH. Genomics 1995, 28:66-73.
23. Selcuklu S.D., Donoghue M.T., Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans. 2009, 37:918-925.
24. Steele-Perkins G., Plachez C., Butz K.G., Yang G., Bachurski C.J., Kinsman S.L., Litwack E.D., Richards L.J., Gronostajski R.M. The transcription factor gene Nfib is essential for both lung maturation and brain development. Mol. Cell Biol. 2005, 25:685-698.
25. Tuna M., Smid M., Zhu D., Martens J.W., Amos C.I. Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. PLoS One 2010, 5:e15094.